International Journal of Sport Studies for Health

Journal Homepage



Advancing Human Performance: Genomic Innovations and Ethical Imperatives in Sports Science

Danial. Kahrizi^{1*}

* Corresponding author email address: dkahrizi@modares.ac.ir

Editor	Reviewers
Özgür Eken®	Reviewer 1: Mohammadreza Zarbakhsh Bahri ©
Associate Professor, Inonu	Associate Professor 'Department of Psychology, Tonekabon Branch, Islamic Azad
University, Malatya, Turkey	University, Tonekabon, Iran. Email: M.Zarbakhsh@Toniau.ac.ir
ozgureken86@gmail.com	Reviewer 2: Seyed Mohammad Hosseini
	Assistant Professor, Department of Health and Rehabilitation in Sports, Shahid
	Beheshti University, Tehran, Iran. Email: moh_hosseini@sbu.ac.ir

1. Round 1

1.1 Reviewer 1

Reviewer:

Add "CRISPR-Cas9" to the keywords to reflect a central theme discussed in the article and improve discoverability.

This is a strong opening, but consider referencing the broader theoretical framework or model (e.g., epigenetics or systems biology) that supports this shift to contextualize the argument better.

This sentence is highly technical; a brief explanation of what MSTN and COL5A1 genes do would improve accessibility for multidisciplinary readers.

It would be useful to specify the type of ethical concerns (e.g., consent, equity, long-term health impacts) to ground the argument in bioethics literature.

Consider citing a guideline or policy recommendation (e.g., GDPR, HIPAA) to strengthen the normative argument around privacy standards.

Author revised the manuscript and uploaded the updated document.

¹ Biotechnology Department, Tarbiat Modares University, Tehran Iran



1.2 Reviewer 2

Reviewer:

The cited study is significant, but it would be helpful to explain how these molecular adaptations specifically translate into measurable performance metrics (e.g., VO₂ max or endurance thresholds).

Consider elaborating briefly on how mitochondrial biogenesis contributes to endurance performance to assist non-specialist readers.

Clarify whether the ban includes both therapeutic and enhancement uses, and whether it applies to somatic vs. germline edits, as these distinctions have regulatory implications.

Please specify the editorial's title or issue date to allow readers to locate the reference more easily.

Recommend expanding this point with examples (e.g., African or Southeast Asian nations) to emphasize the global equity dimension more concretely.

Author revised the manuscript and uploaded the updated document.

2. Revised

Editor's decision after revisions: Accepted. Editor in Chief's decision: Accepted.



2